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Statins are independently associated with reduced
mortality in patients undergoing infrainguinal
bypass graft surgery for critical limb ischemia
Andres Schanzer, MD,a Nathanael Hevelone, MPH,b Christopher D. Owens, MD,c
Joshua A. Beckman, MD, MS,d Michael Belkin, MD,c and Michael S. Conte, MD,b,c Worcester and Boston, Mass
Objective: Evidence suggesting a beneficial effect of cardioprotective medications in patients with lower extremity
atherosclerosis derives largely from secondary prevention studies of heterogeneous populations. Patients with critical
limb ischemia (CLI) have a large atherosclerotic burden with related high mortality. The effect of such therapies in this
population is largely inferred and unproven.
Methods: The Project of Ex-Vivo vein graft Engineering via Transfection III (PREVENT III) cohort comprised 1404
patients with CLI who underwent lower extremity bypass grafting in a multicenter, randomized prospective trial testing
the efficacy of edifoligide for the prevention of graft failure. Propensity scores were used to evaluate the influence of
statins, -blockers, and antiplatelet agents on outcomes while adjusting for demographics, comorbidities, medications,
and surgical variables that may influence drug use. Primary outcomes were major adverse cardiovascular events <30 days,
vein graft patency, and 1-year survival assessed by Kaplan-Meier method. Potential determinants of 1-year survival were
modeled using a multivariate Cox regression.
Results: In this cohort, 636 patients (45%) were taking statins, 835 (59%) were taking -blockers, and 1121 (80%) were
taking antiplatelet drugs. Perioperative major adverse cardiovascular events (7.8%) and early mortality (2.7%) were not
measurably affected by the use of any drug class. Statin use was associated with a significant survival advantage at 1 year
of 86% vs 81% (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.52-0.98; P  .03) by analysis of both
unweighted and propensity score-weighted data. Use of -blockers and antiplatelet drugs had no appreciable impact on
survival. None of the drug classes were associated with graft patency measures at 1 year. Significant predictors of 1-year
mortality by Cox regression modeling were statin use (HR, 0.67; 95% CI, 0.51-0.90; P  .001), age >75 (HR, 2.1; 95%
CI, 1.60-2.82; P  .001), coronary artery disease (HR, 1.5; 95% CI, 1.15-2.01; P  .001), chronic kidney disease stages
4 (HR, 2.0; 95% CI, 1.17-3.55; P  .001) and 5 (HR, 3.4; 95% CI, 2.39-4.73; P < .001), and tissue loss (HR, 1.9; 95%
CI, 1.23-2.80; P  .003).
Conclusions: Statin use is associated with improved survival in CLI patients 1 year after surgical revascularization. Further
studies are indicated to determine optimal dosing in this population and to definitively address the question of
relationship to graft patency. These data add to the growing literature supporting statin use in patients with advanced
peripheral arterial disease. ( J Vasc Surg 2008;47:774-81.)Peripheral arterial disease (PAD) occurs commonly,
with an estimated prevalence as high as 21% in patients aged
65 years.1-6 It has been well documented that the pres-
ence of PAD elevates the risk of cardiovascular events,
including major limb loss, myocardial infarction, stroke,
and death.4,7,8 It is therefore no surprise that in the subset
of patients who manifest critical limb ischemia (CLI), the
most advanced form of PAD, cardiovascular event rates are
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774high9 and may even surpass those seen in patients with
symptomatic coronary artery disease (CAD).10
The main emphasis on treatment for patients with CLI
has tended to focus on the limb, with surgical bypass
grafting and endovascular methods dominating the litera-
ture, rather than strategies of risk factor modification and
stabilization of the global atherosclerotic burden.6,11,12
Although the American Heart Association and the Ameri-
can College of Cardiology have endorsed a variety of pre-
vention guideline documents for CAD patients based on
level I data,13-15 the development of treatment guidelines
specific for patients with PAD has been hampered by a
relative lack of robust evidence.16
Various reports have demonstrated that cardioprotec-
tive medications such as statins, -blockers, and antiplatelet
agents are associated with a decreased cardiovascular event
rate17-21 in the PAD population. These studies have been
conducted in heterogeneous populations, however, and
little is known about the effectiveness of these drugs in
patient population at greatest risk—patients with CLI.
In the landmark Heart Protection Study (HPS),17 statins
were clearly demonstrated to have a protective effect in
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major vascular events. The HPS broadly defined PAD “as
a history of intermittent claudication . . . or previous
peripheral arterial revascularization procedure, amputa-
tion, or aneurysm repair.”22
Other smaller studies have examined the effects of
-blockers and statins on perioperative events in vascular
surgery patients, often including aneurysm repair as a sig-
nificant proportion of the cohort.23-26 As a result, the exact
role of cardioprotective medications remains unclear in
patients with CLI, particularly those undergoing attempts
at limb salvage. An important corollary question for CLI
patients relates to the influence of these medications on the
limb revascularization per se, with some recent studies
suggesting improved bypass graft patency.27-29
This study sought to address this topic by using the
Project of Ex-Vivo vein graft Engineering via Transfection
(PREVENT III) database. PREVENT III was a prospec-
tive, randomized, double-blinded, multicenter trial de-
signed to examine the efficacy of edifoligide, a novel phar-
macologic agent, in preventing autogenous vein graft
failure in patients who underwent an infrainguinal bypass
grafting (IBG) procedure exclusively for the treatment of
CLI.30 Details of the trial design have been described
elsewhere,31 and only relevant features are briefly reviewed
here. Edifoligide is a short, double-stranded DNA mole-
cule that inhibits cell cycle gene expression and was hypoth-
esized to reduce neointimal hyperplasia. In the primary
PREVENT III analysis, however, the treatment of vein
grafts with edifoligide was found to confer no benefit on
the prespecified primary and secondary end points.30 The
current study used this unique database to assess the influ-
ence of cardioprotective medications on early (30-day) and
mid-term (1-year) outcomes in patients undergoing vein
bypass graft surgery for CLI.
PATIENTS AND METHODS
The PREVENT III cohort. The study cohort con-
sisted of 1404 patients with CLI drawn from 83 commu-
nity and university hospitals located in Canada and the
United States. Each participating institution underwent
independent review of the study and received approval
from its respective Institutional Review Board (IRB). En-
rollment was initiated in November 2001 and completed in
October 2003. Pertinent characteristics of the study popu-
lation are summarized in Table I, and additional detailed
informationmay be found in the primary trial report.30 The
inclusion criteria specified patients aged 18 years who
underwent IBG with autogenous vein for CLI, which was
defined as gangrene, nonhealing ischemic ulcer, or isch-
emic rest pain. Exclusion criteria included claudication as
an indication for IBG surgery or use of a nonautogenous
conduit.
Demographic variables and a detailed vascular exami-
nation were collected before surgery as part of a compre-
hensive history and physical examination. The decision to
prescribe any concomitant medication before, during, or
after surgery was not protocol-driven and was left to thediscretion of the operating surgeon. Accordingly, medica-
tion usage varied according to individual clinical practice
patterns. For all patients, medication use at entry into the
study (before the index surgery) and at the time of dis-
charge (after the index surgery) was recorded by protocol.
The study subjects were followed up for 1 year from the
time of IBG surgery, with graft ultrasound surveillance per-
formed at 1, 3, 6, and 12months, and a physical examination,
including an ankle-brachial index, performed at 1, 3, 6, 9, and
12months. Outcome events in PREVENT III were tracked
by investigators and their study staff at participating centers
using specifically designed case report forms, supported by
source documentation. All data were audited by a contract
research organization before being entered into the trial
database.
Adverse event reporting 30 days after treatment,
including major adverse cardiovascular events (MACE),
was mandated by theUnited States Food andDrug Admin-
istration, conformed to federal regulatory guidelines (21
CFR Part 312) adverse events reporting, and used accepted
clinical definitions and the Medical Dictionary for Regula-
tory Affairs (MedDRA, Reston, VA) preferred terminol-
ogy. All MACEwould be considered serious adverse events
by regulatory guidelines and were therefore reported
promptly to the sponsor (medical monitor) and to the local
IRBs, with appropriate supporting documentation. A clin-
ical events classification committee performed a blinded
independent review of each case of index graft failure. A
total of 44 patients (3.2%) either withdrew or were lost to
follow-up in PREVENT III.
Study design. The cohort was analyzed to determine
the influence of statin use, -blocker use, and antiplatelet
drug use on both 30-day and 1-year outcomes. Data relat-
ing to other drug categories of interest, for example, other
antihypertensive classes or immunomodulatory drugs, were
not available for study. For all 30-day outcome analyses, a
patient’s medication use category (on drug or off drug) was
based entirely according to entry status, regardless of dis-
charge status. Conversely, for all 1-year analyses, the pa-
tient’s medication use category was based entirely accord-
ing to discharge status, regardless of entry status.
The primary end points at 30 days were death and
composite MACE, defined as any myocardial infarction,
stroke, or death. The primary end points at 1 year were
primary patency, secondary patency, number of rehospital-
izations, and survival. All end points were defined in accor-
dance with the published standards for outcomes reports in
lower extremity revascularization32 and assessed by the
Kaplan-Meier method.
Statistical analysis. Baseline characteristics and the
incidence of MACE between users and nonusers of each
drug class were assessed by using the Pearson 2 analysis for
categoric variables and the Student t test for continuous
variables. Differences in primary and secondary patency and
survival were compared by category for each medication
class. These time-to-event end point analyses were per-
formed by using the Kaplan-Meier method, and the treat-
ment groups were compared with the log-rank test.
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generation of a propensity score to predict the probability of
exposure to a certain treatment enables one to control for the
aggregate amount of measured confounding. Accordingly, to
adjust for different baseline demographic, comorbid, and sur-
gical covariates (Table I), propensity score models were cre-
ated for each drug class. In this propensity score approach, the
data for each patient were weighted by the product of the
inverse of the probability of receiving his or her treatment
given the demographic and surgical characteristics specified in
Table I with the baseline probability of group membership.
Once these weights were obtained and assessed for function-
ality of achieving balance in previously unbalanced covariates
Table I. Patient characteristics in the PREVENT III coho
discharge
Variable
Statin use
Yes (n  636) No (n  768)
Age, mean  SD years 68.5  10.5 68.5  13.0
Female sex, % 38.8 33.9
Race/ethnicity, %
Caucasian 76.4a 69.1a
African American 13.4a 21.4a
Other 10.2 9.5
Risk factors for PAD, %
Smoking 73.9 73.7
High cholesterol 73.3a 21.9a
Diabetes mellitus 72.0a 57.6a
Hypertension 85.4a 78.5a
CAD 52.7a 32.7a
Dialysis-dependent 12.6a 17.7a
Prior IBG 32.6a 22.9a
CLI criterion, %b
Rest rain 24.5 22.3
Tissue loss 75.5 73.7
Medications, %
Statin 100a 0a
-blocker 67.1a 53.1a
Aspirin 83.8a 76.6a
Edifoligide 49.7 50.9
Surgical characteristics, %
Proximal anastomosis
CFA 46.7 50.8
SFA 25.3 24.2
Popliteal 16.7 17.5
Distal anastomosis
Popliteal 33 32.2
Tibial 52.5 53.9
Pedal 11.3 12.2
Conduit diameter
3 mm 5.5 6.51
3-3.49 mm 37.1 40.1
3.5 mm 52.2 50.8
Institutional setting, %
US, academic 62.9a 54.3a
US, private 29.7a 39.8a
Canada 7.39 5.86
CAD, Coronary artery disease; CFA, common femoral artery; CLI, critical
PREVENT III, Project of Ex-Vivo vein graft Engineering via Transfection;
aP  .05. Propensity scoring was used to generate weights in order to balan
Appendix Table, online only).(Appendix Table, online only), they were applied to subjectsin a univariate proportional hazards model comparing the
treatment strategies.
Finally, a separate Cox proportional hazards model
with backwards elimination was used to identify indepen-
dent predictors for 1-year mortality. Variables incorporated
in this model were:
● demographics—age, sex, race, institutional setting;
● PAD risk factors—tobacco use, diabetes mellitus, hy-
pertension, CAD, prior coronary artery bypass graft,
chronic kidney disease class, prior IBG;
● CLI criterion—rest pain, tissue loss;
cording to medication use recorded at time of hospital
-Blocker use Antiplatelet use
n  835) No (n  569) Yes (n  1121) No (n  283)
 11.2 67.5  11.9 68.5  11.6 68.9  11.3
36.1 36.2 35 40.6
73.7 70.7 74.2a 65.4a
16.7 19.3 16.4a 23.0a
9.7 10 9.37 11.7
71.4a 77.3a 74.6 70.7
50.5a 37.3a 45.9 42.4
67.5a 59.1a 65.6a 58.3a
87.7a 72.8a 81.8 80.9
48.9a 31.3a 44.5a 30.7a
14.4a 16.9a 14.5a 19.1a
28.7 25.1 26.7 29.7
24.1 27.6 26.2 22.6
75.9 72.4 73.8 77.4
51.1a 36.7a 47.5a 52.5a
00a 0a 62.1a 49.1a
83.4a 74.7a 100a 0a
50.8 49.7 48.8 53
48.3 49.9 48.9 49.1
24.1 25.7 24.5 25.4
18 15.8 17.1 17
30.9 35 32 34.6
53.9 52.4 53.4 53
12.8 10.4 12 11
4.55 8.26 6.24 5.3
38.3 39.4 38.6 39.2
51.7 51 50.8 54.1
68.1a 43.6a 62.0a 43.1a
25.8a 49.2a 31.3a 50.9a
6.11 7.2 6.7 6.01
ischemia; IBG, infrainguinal bypass graft; PAD, peripheral arterial disease;
superficial femoral artery; US, United States.
covariates above resulting in no significant differences between groups (seert ac
Yes (
69.2
1
limb
SFA,
ce all● medication usage—statin, -blocker, antiplatelet; and
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diameter.
Comparisons of the number of rehospitalizations were
made withWilcoxon rank sum tests for nonparametric data.
All tests were considered statistically significant at   .05
(P  .05, two-tailed). All analyses were performed using
SAS 9.1 software (SAS Inc, Cary, NC).
RESULTS
Early (30-day) major adverse cardiovascular events
and death. For the 1404 patients in the entire study
cohort, the incidence of MACE was 7.8% and the 30-day
mortality rate was 2.6%. Use of any of the studied drug
classes was not found to be significantly associated with
either MACE or death at 30 days (Table II). Although use
of -blockers was associated with the incidence of 30-day
MACE (9.5% vs 6.2%, P .02) in the unadjusted data, this
effect lost significance once propensity score weighting was
used (9.0% vs 7.4%, P  .28). It should be noted that
although the data reported for 30-day outcomes used
medications recorded at study entry (see “Methods”),
these analyses were repeated using discharge medication
data, with no significant difference in the findings.
Graft patency at 1 year. No association was found
between any drug class and 1-year primary or secondary
Table II. Early (30-day) major adverse cardiovascular eve
use,a before and after propensity model weighting
Variable
Statin use
PYes No
MACE, %
Unweighted 8.7 7 .23
Weighted 7.4 7.1 .84
Death, %
Unweighted 2.6 2.7 .92
Weighted 2.2 2.7 .5
MACE, Major adverse cardiovascular event.
aMedication use recorded at time of hospital admission.
Table III. Patency and survival at 1 year according to stat
propensity model weighting
Statin use
PYes No
Primary patency, %
Unweighted 55.1 55.6 .78
Weighted 56.2 55.5 .8
Secondary patency, %
Unweighted 76 76.8 .61
Weighted 76 76.8 .66
Survival, %
Unweighted 85.9 81.2 .02
Weighted 86 81.4 .04
aMedication use recorded at time of hospital discharge.graft patency (Table III). In the unadjusted analysis, astatistically significant 1-year primary patency advantage
was seen in the patients taking -blockers. However, this
effect was not significant when the data were adjusted by
the propensity score model (57.7% vs 53.8%, P  .16).
Cumulative number of patient rehospitalizations
occurring more than 1-year after bypass graft surgery.
The mean number of rehospitalizations during the year
after bypass graft surgery was 1.53 for the entire study
population. Patients taking -blockers required signifi-
cantly more rehospitalizations (1.61 vs. 1.41, P  .03)
during the year after surgery (Table IV). Neither statin use
nor antiplatelet agent use was associated with the number
of required rehospitalizations.
When the cause for admission was limited to cardiovas-
cular etiology specifically, the mean number of required
rehospitalizations for the entire cohort decreased to 0.16.
None of the cardioprotective medications, other than
-blockers (0.18 vs 0.12, P  .02), demonstrated a signif-
icant association with the number of required cardiovascu-
lar rehospitalizations.
Survival at 1 year. The overall Kaplan-Meier estimate
for 1-year survival in the PREVENT III cohort was 84%. A
significant survival advantage was seen in patients taking
statins compared with those not prescribed statins (Fig).
This effect was seen on the unadjusted analysis (85.9% vs
nd death according to statin, -blocker, and antiplatelet
locker use
P
Antiplatelet use
PNo Yes No
6.2 .02 8.7 5.8 .06
7.4 .28 8.9 6.6 .2
2.6 .94 3.2 1.5 .06
3 .67 3.4 1.6 .06
-blocker, and antiplatelet use,a before and after
-Blocker use
P
Antiplatelet use
Ps No Yes No
.7 52 .02 54.9 56.7 .65
.7 53.8 .16 55.2 60.6 .12
.7 74.3 .08 77.5 73.3 .23
.5 75.1 .19 77.6 76.2 .73
.8 84.1 .49 83.9 81 .26
.2 83.7 .66 83.9 81.5 .38nts a
-B
Yes
9.5
9
2.7
2.6in, 
Ye
57
57
77
77
82
8381.2%, P  .02) and persisted on the propensity score–
0.1
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patients taking statins had a hazard ratio (HR) of death of
0.71 (95% confidence interval [CI] 0.52-0.98; P  .03).
Neither -blocker use nor antiplatelet drug use was associ-
ated with 1-year survival (Table III).
A multivariable Cox regression model of survival (Ta-
ble V) that controlled for demographic variables, PAD risk
factors, CLI criterion, medication usage, and surgical char-
acteristics also identified statin use as a significant predictor
of 1-year mortality (HR, 0.68; 95% CI, 0.51-0.90; P 
.01). Additional significant independent predictors of mor-
tality were age 75 (HR, 2.13; 95% CI, 1.60-2.82), pres-
ence of CAD (HR, 1.52; 95% CI, 1.15-2.01), chronic
kidney disease stages 4 (HR, 2.04; 95% CI, 1.17-3.55) and
5 (HR, 3.4; 95% CI, 2.39-4.73), and tissue loss (ulcer or
Table IV. Cumulative number of rehospitalizations at 1 y
recorded at time of hospital discharge
Rehospitalizations
Statin use
PYes No
Total No. 1.6 1.5 .37
Cardiovascular, No. 0.16 0.15 .73
Fig. One-year survival by the Kaplan-Meier method according to
patients who were taking statins (dashed line) vs not taking statins
(solid line) recorded at the time of hospital discharge.A,Weighted
propensity score for survival (P .03). B,Unweighted propensity
score for survival (P  .02).gangrene) on presentation (HR, 1.86; 95% CI, 1.23-2.80).DISCUSSION
Patients who present with CLI bear a large systemic
burden of atherosclerotic disease and therefore face not
ccording to statin, -blocker, and antiplatelet use
-Blocker use
P
Antiplatelet use
PNo Yes No
1.4 .03 1.5 1.5 .89
8 0.12 .02 0.16 0.13 .34
Table V. Multivariate analysis identifying impact of
predictors of mortality at 1 year in the PREVENT III
population
Variable Hazard ratio (95% CI) P
Age 75 2.13 (1.60-2.82) .01
Female sex 1.09 (0.81-1.46) .58
Race/ethnicity
White 1.0 (ref) . . .
African American 0.82 (0.56-1.20) .3
Other 0.97 (0.63-1.50) .9
Risk factors for PAD
Smoking 0.93 (0.68-1.28) .65
Diabetes mellitus 1.31 (0.96-1.79) .09
Hypertension 1.04 (0.70-1.54) .84
Coronary artery disease 1.52 (1.15-2.01) .01
Prior IBG 0.84 (0.61-1.16) .3
Chronic kidney disease
Stage 4 2.04 (1.17-3.55) .01
Stage 5 3.36 (2.39-4.73) .01
CLI criteriona
Rest pain 1.0 (ref) . . .
Tissue loss 1.86 (1.23-2.80) .01
Medications
Statin 0.68 (0.51-0.90) .01
-blocker 1.10 (0.82-1.46) .52
Aspirin 0.86 (0.63-1.19) .37
Surgical characteristics
Proximal anastomosis
CFA 1.0 (ref) . . .
SFA 0.89 (0.64-1.23) .47
Popliteal 0.65 (0.42-1.00) .05
Distal anastomosis
Popliteal, AK 1.0 (ref) . . .
Popliteal, BK 1.22 (0.86-1.72) .26
Tibial 0.82 (0.48-1.40) .48
Pedal 0.86 (0.54-1.36) .52
Conduit diameter
3 mm 1.40 (0.85-2.30) .19
3-3.49 mm 0.83 (0.62-1.10) .21
3.5 mm 1.0 (ref) . . .
Institutional setting
US, academic 0.90 (0.68-1.20) .48
US, private 1.0 (ref) . . .
Canada 0.54 (0.27-1.09) .09
AK, Above knee; BK, below the knee; CFA, common femoral artery; CLI,
critical limb ischemia; IBG, infrainguinal bypass graft; PAD, peripheral
arterial disease; PREVENT III, Project of Ex-Vivo vein graft Engineering via
Transfection; SFA, superficial femoral artery; US, United States.
aMost severe.ear a

Yes
1.6only the immediate risk of limb loss34 but also an increased
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would seemingly have much to gain from the use of cardio-
protective medications, the efficacy of these drugs in the
setting of such globally advanced atherosclerosis cannot be
assumed from other cohorts. The PREVENT III trial, with
its high-risk CLI population, provides a relevant database
for examination. The salient finding of this study is that the
use of statin drugs was associated with a significant 1-year
survival benefit in patients undergoing surgical bypass
grafting for CLI. The Kaplan-Meier analysis further sug-
gests that the benefit continues to increase with time and
might be even greater with longer-term follow-up.
A previously published report by the PREVENT trial-
ists examined the determinants of usage of medications and
their effects on immediate perioperative outcomes.35 The
present study adds to this work by using sophisticated
models to assess the effect of cardioprotective medications
on both 30-day and 1-year outcomes. The patients in this
cohort of 1404 who did not receive statins experienced an
approximate 40% increase in the risk of death at 1-year. This
effect was demonstrated both in the propensity score–
weighted analysis (HR, 1.40; 95% CI, 1.02-1.92) and in
the Cox proportional hazards model (HR, 1.47; 95% CI,
1.11-1.96).
These findings are consistent with observational studies
that have examined the effects of statins, albeit in hetero-
geneous PAD populations.18,23,36 The largest of these,
conducted by Feringa et al,18 enrolled 1374 patients with
PAD andmonitored them for a mean duration of 6.4 years.
The authors demonstrated a strong independent associa-
tion between statin use and all-cause mortality (HR, 1.41
for nonusers; P  .0001).18
TheHPS is the largest trial to assess the effects of statins
on major morbidity and mortality.17 The investigators
enrolled 20,000 patients deemed to be at high risk for
cardiovascular events and randomized them to receive ei-
ther simvastatin (40 mg) or placebo. The survival analysis
demonstrated that treatment with a statin was significantly
associated with a decrease in all-cause mortality (12.9% vs
14.7%, P .0003) and that this effect was primarily driven
by the reduction in death from vascular causes (7.6% vs
9.1%, P .0001). A recently published subgroup analysis22
focusing specifically on 6748 patients with documented
PAD did not include mortality data or stratify the patients
according to the degree of limb ischemia. However, the
authors demonstrated a significant relative reduction of
22% in the rate of a first major vascular event in the
simvastatin treatment arm (P  .0001) compared with
placebo.
A wide body of literature has developed showing that
-blockers24,37,38 and antiplatelet agents20,39 provide ben-
efit in patients with PAD, including those undergoing
vascular reconstructions. Statin therapy has also been re-
cently associated with decreased perioperative morbidity
and mortality25,26,36 in vascular surgery patients. Thus, the
negative findings for both perioperative and long-term
events in this study must be interpreted with great caution
and have several important limitations.First and foremost, patients were not randomized to
treatment with these medications in PREVENT III. At the
time PREVENT III was initiated, extensive data were
already available suggesting a benefit for -blockers and
antiplatelet agents in peripheral vascular patients, although
much less so for statins (note the HPS study was published
1 year after PREVENT III began enrollment). This was
reflected by the relative use of these drug classes in the
cohort, suggesting important differences in prescribing
patterns. It is possible that the appropriate patients—those
in most need of aggressive medical management—were
selected for -blocker and antiplatelet agent treatment
upfront by their physicians (confounding by indication). As
a result, if the treated patients were at higher baseline risk
than those not treated, a significant drug effect would be
difficult to identify.
Propensity score modeling has been used in this situa-
tion to effectively control for the aggregate amount of
confounding contributed by various factors.33,40,41 None-
theless, although this methodology tries to emulate the
advantages of a randomized trial, it does not achieve them
completely; unlike a randomized trial that controls for
measured and unmeasured confounders, a propensity score
can only equalize observed confounders between groups.
Therefore, the failure to see an association between
-blockers or antiplatelet agents with the outcomes mea-
sured in this study may be due to the presence of unrecog-
nized confounders that were not included in the propensity
score models.
Second, this study may have lacked statistical power to
demonstrate certain associations. This is particularly rele-
vant to the analysis of 30-day outcomes where the limited
number of events has been noted in this and other stud-
ies.42 Analysis of some 1-year outcomes may also have been
limited by power. Looking at -blockers as an example,
although the power to detect a 20% graft patency difference
was80% (  .05, HR, 1.20; total number events, 554),
the power to detect a 20% survival difference was well below
80% (  .05; HR, 1.20; total number events, 228). For
antiplatelet therapy, the combination of a small cohort of
nonusers (20%) and a limited number of events greatly
reduces the ability to measure benefit in this study.
Because of the aforementioned limitations inherent to
the context of this study, failure to show an association
between certain outcomes and medications on this analysis
should be considered hypothesis generating only. Specifi-
cally, we would not advocate any change in the use of
-blockers and antiplatelet agents in this high-risk popula-
tion, and we continue to prescribe them for our patients.
However, this study highlights that the optimal approach
to reduce short- and long-term cardiovascular risk remains
undefined for the CLI patient and requires further prospec-
tive investigation.
Some recent reports have suggested a potential benefit
for graft patency for patients using statin drugs.27,29,43 In
this analysis, we did not observe any significant relationship
between statin use and graft outcomes. The study by Ab-
bruzzese et al27 contrasts with the PREVENT III cohort in
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April 2008780 Schanzer et alseveral important ways, including single-center experience,
a lower-risk nature of the conduits used (all single-segment
great saphenous veins), no reoperative cases, and a longer
duration of follow-up.27 In contrast, the PREVENT III
population included a significant proportion of high-risk
conduits (23% were nonsingle segment great saphenous
vein grafts), including 17% reoperative cases, that were
performed in 83 hospitals in the trial.
Of note, recent work has suggested that systemic inflam-
mation, as measured by levels of high-sensitivity C-reactive
protein, may be linked to cardiovascular events and vein graft
failure in patients undergoing lower extremity bypass graft
surgery.44 The anti-inflammatory properties of statins may
therefore provide a plausible mechanism for benefit in
patients undergoing bypass graft surgery, adding to the
rationale for prospective studies to definitively address this
question.
Finally, this data set contains only two static time points
detailing whether or not a patient was receiving statin
therapy. No data were available on dosages, the duration of
treatment either before or after surgery, or on the degree of
patient compliance with prescribed medications.
One salient feature of this analysis that deserves re-
emphasis is the underutilization of the three drug catego-
ries studied. In this cohort, at the time of discharge after
major reconstructive vascular surgery, only 45% of patients
were prescribed statins, 59% were prescribed -blockers,
and 80% were prescribed antiplatelet agents. This under-
treatment of patients with PAD has been echoed by several
other published reports6,11,12 and deserves more attention.
CONCLUSIONS
To our knowledge, this is the first report to demon-
strate that statin use is associated with improved survival,
specifically in CLI patients, 1-year after surgical revascular-
ization. Further studies are indicated to determine optimal
dosing in this high-risk population and to definitively ad-
dress the question of effects on graft patency. These data
add to the growing literature supporting statin use in
patients with advanced PAD.
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Volume 47, Number 4 Schanzer et al 781.e1Appendix Table (online only). Patient characteristics in the PREVENT III cohort according to medication use after
weighting by the propensity scorea
Characteristic
Statin usea -Blocker usea Antiplatelet usea
Yes No Yes No Yes No
Age, mean  SD years 68.6  12.1 68.6  11.4 68.7  11.6 68.5  11.1 68.5  11.6 68.9  11.3
Female sex, % 35 36.1 35.9 36.1 36.1 35.7
Race/ethnicity, %
Caucasian 73.8 72.3 72.3 71.7 72.5 71.9
African American 16.9 17.9 17.4 17.8 17.1 17.1
Other 9.3 9.8 10.3 10.5 10.4 11
PAD risk factors, %
Smoking 73.7 73.8 73.7 75.5 73.6 72.7
High cholesterol . . . . . . 44.9 43.6 45.2 45.4
Diabetes mellitus 62.5 63.5 64.4 65.1 64.1 64.7
Hypertension 79.3 81.7 82.4 82 81.7 83.3
CAD 40.2 41.4 42.3 41.9 41.8 42.1
Dialysis-dependent 13.3 15.4 16.1 15.6 15.4 16.4
Prior IBG 26.8 27 26.5 25.7 27.2 26.5
CLI criterion, %
Rest pain 24.6 25.6 25.6 24.6 25.4 26.2
Tissue loss 75.4 74.4 74.4 75.4 74.6 73.8
Medications, %
Statin . . . . . . 46.7 46 49.8 49.9
-Blocker 57.6 59.1 . . . . . . 59.6 60.4
Aspirin 80.7 79.8 80.5 80 . . . . . .
Edifoligide 47.9 48.4 49.8 48.4 49.8 51.6
Surgical characteristics, %
Proximal anastomosis
CFA 48.4 49.8 48.7 50.8 49 49.9
SFA 27.4 25 24.9 22.7 24.7 24.9
Popliteal 15.7 16.9 17.2 17.3 17.2 17.6
Distal anastomosis
Popliteal 30.5 32.8 32.6 31.8 32.9 32.4
Tibial 56 53.4 53.3 55.8 53.5 53.4
Pedal 11.1 11.8 11.5 10.3 11.7 11.2
Conduit diameter
3 mm 5.76 6.12 5.86 5.43 5.99 6.36
3-3.49 mm 37.9 38.6 37.6 38.4 38.7 37.2
3.5 mm 52.7 50.9 52.9 52.1 51.5 52.2
Institutional setting, %
US, academic 58.9 58.2 58.5 58.1 58.2 57.8
US, private 35.7 35.2 35 35.4 35.2 36.3
Canada 5.85 6.09 6.54 6.54 6.52 5.93
CAD, Coronary artery disease; CFA, common femoral artery; CLI, critical limb ischemia; IBG, infrainguinal bypass graft; PAD, peripheral arterial disease;
PREVENT III, Project of Ex-Vivo vein graft Engineering via Transfection; SFA, superficial femoral artery; US, United States.
aAll values of P  .05.
